Rituximab and Fludarabine Combination Produces Long-Term Remissions in CLL
Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate
XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study
Study Suggests Biomarker For Resistance to Tamoxifen
Radiation, Tamoxifen After Surgery Reduce Breast Cancer Occurrence
Aflibercept-Docetaxel Combination Misses Primary Survival Endpoint
Patients Who Smoke In Treatment Do Worse Than Those Who Quit
Dendritic Cell Vaccine May Boost Median Survival
Decline In Breast Cancer May Be Related to Drop In HT
Triple-Negative Breast Cancer Increases With Number of Births
PSA Velocity Poor Predictor Of Prostate Cancer Occurrence
Statins Associated With Lower Risk Of High-Grade Prostate Cancer
Mentholated Cigarettes Cause No More Lung Cancer, Deaths
Clinical Trials Approved By NCI CTEP Last Month
FDA Approves BMS’s Yervoy For Metastatic Melanoma
Trending Stories
- Moving from mandate to mission: Community outreach and engagement at NCI-designated cancer centers
“COE is broken.” - Trump 2016: A look back at the 45th president’s impact on oncology
- Don’t confirm RFK Jr. for HHS, 77 Nobel laureates urge the Senate
- Art exhibit at University of Miami Sylvester bridges North and South America
- VCU awarded $9M from NCI to establish Cancer Control Equity Research Center
- The Cancer Letter’s most-read stories of 2024
